These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22183643)

  • 1. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.
    Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
    Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas.
    Oudijk L; Papathomas T; de Krijger R; Korpershoek E; Gimenez-Roqueplo AP; Favier J; Canu L; Mannelli M; Rapa I; Currás-Freixes M; Robledo M; Smid M; Papotti M; Volante M
    Neuroendocrinology; 2017; 105(4):384-393. PubMed ID: 28122379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.
    Favier J; Plouin PF; Corvol P; Gasc JM
    Am J Pathol; 2002 Oct; 161(4):1235-46. PubMed ID: 12368197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
    Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
    Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
    Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
    Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
    Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.
    Lussey-Lepoutre C; Buffet A; Morin A; Goncalves J; Favier J
    Cell Tissue Res; 2018 May; 372(2):379-392. PubMed ID: 29427052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
    Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
    Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
    Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
    Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
    Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C
    Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
    Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma.
    Burnichon N; Lepoutre-Lussey C; Laffaire J; Gadessaud N; Molinié V; Hernigou A; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
    Eur J Endocrinol; 2011 Jan; 164(1):141-5. PubMed ID: 20923864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.
    Yao L; Schiavi F; Cascon A; Qin Y; Inglada-Pérez L; King EE; Toledo RA; Ercolino T; Rapizzi E; Ricketts CJ; Mori L; Giacchè M; Mendola A; Taschin E; Boaretto F; Loli P; Iacobone M; Rossi GP; Biondi B; Lima-Junior JV; Kater CE; Bex M; Vikkula M; Grossman AB; Gruber SB; Barontini M; Persu A; Castellano M; Toledo SP; Maher ER; Mannelli M; Opocher G; Robledo M; Dahia PL
    JAMA; 2010 Dec; 304(23):2611-9. PubMed ID: 21156949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
    Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
    Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.